Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2009. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of director share awards rather than a financial performance report.
Material Changes
On March 31, 2009, Non-Executive Directors were provisionally allocated awards of Ordinary shares and American Depository Shares (ADSs) for the service period of January 1, 2009, to March 31, 2009. The allocation price was set at £10.55 per Ordinary share and $30.21 per ADS. These allocations were communicated to the Company and the Directors on April 1, 2009.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Allocation Date: Awards were provisionally allocated on March 31, 2009, and notified on April 1, 2009.
- Share Price Basis: Allocations were based on £10.55 per Ordinary share and $30.21 per ADS.
- Beneficiaries: Awards were distributed to ten Non-Executive Directors, including Sir Christopher Gent, Prof Sir Roy Anderson, and Dr Stephanie Burns.
- Volume: Specific share counts were allocated to each director, ranging from approximately 740 to 3,199 shares/ADSs.